Trentium Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 04-07-2024
- Paid Up Capital ₹ 0.10 M
as on 04-07-2024
- Company Age 6 Year, 13 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 72.00 M
as on 04-07-2024
- Revenue 3.68%
(FY 2023)
- Profit -9.71%
(FY 2023)
- Ebitda -448.43%
(FY 2023)
- Net Worth 52.46%
(FY 2023)
- Total Assets 5.96%
(FY 2023)
About Trentium Lifesciences
The Corporate was formerly known as Griffon Biometrix Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.20 Cr.
Dharmendra Shah, Chetankumar Shah, Brijesh Patel, and Two other members serve as directors at the Company.
- CIN/LLPIN
U33208GJ2018PTC105028
- Company No.
105028
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Oct 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Trentium Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetankumar Shah  | Director | 30-Oct-2018 | Current |
| Dharmendra Shah | Director | 30-Oct-2018 | Current |
| Brijesh Patel | Director | 30-Oct-2018 | Current |
| Rasik Haria | Director | 30-Oct-2018 | Current |
| Hitesh Shah | Director | 26-Apr-2024 | Current |
Financial Performance and Corporate Structure Insights of Trentium Lifesciences.
Trentium Lifesciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.68% increase. The company also saw a slight decrease in profitability, with a 9.71% decrease in profit. The company's net worth Soared by an impressive increase of 52.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trentium Lifesciences?
In 2023, Trentium Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Sep 2022 | ₹7.20 Cr | Open |
How Many Employees Work at Trentium Lifesciences?
Trentium Lifesciences has a workforce of 3 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trentium Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trentium Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
